Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Stocks News & Analysis
stocks
Apple earnings: Strong performance overpowers headwinds, and we raise our FVE
Our view of Apple shares.
stocks
Coles is winning the supermarket wars but is Woollies the better long-term opportunity?
Our view after first quarter sales updates.
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,182.50 | 24.00 | 0.26% |
| CAC 40 | 8,118.12 | 2.95 | -0.04% |
| DAX 40 | 24,160.32 | 202.02 | 0.84% |
| Dow JONES (US) | 47,562.87 | 40.75 | 0.09% |
| FTSE 100 | 9,716.97 | 0.28 | -0.00% |
| HKSE | 26,158.36 | 251.71 | 0.97% |
| NASDAQ | 23,724.96 | 143.81 | 0.61% |
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% |
| NZX 50 Index | 13,556.30 | 7.98 | 0.06% |
| S&P 500 | 6,840.20 | 17.86 | 0.26% |
| S&P/ASX 200 | 8,894.80 | 36.20 | 0.41% |
| SSE Composite Index | 3,976.52 | 21.73 | 0.55% |